STTKShattuck Labs, Inc.

Healthcare
$5.66+131% 1Y

The financials

Shattuck Labs, Inc. by the numbers

Shattuck Labs, Inc. (STTK) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $15M. For the full year FY2025, revenue was $1.0M (−83% year on year) and net income −$49M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.

Shattuck Labs, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$0$0n/a
Operating income−$16M−$13Mn/a
Net income−$15M−$12Mn/a
Diluted EPS−$0.12−$0.24n/a

Biotechnology

Ranks #134 of 196 by RyuScore

Compare peers
VALN-2.6%
Valneva SE
HELP+2.2%
CYBIN INC.
CTMX-3.1%
CytomX Therapeutics, Inc.
NVCT-0.98%
Nuvectis Pharma, Inc.
SGMT+0.34%
Sagimet Biosciences Inc.
ACRS+12%
Aclaris Therapeutics, Inc.